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Letter to the Editor
Paraoxonase-1 Q192R polymorphism and
risk of sporadic amyotrophic lateral sclerosis
To the Editor:
Paraoxonase-1 (PON1) is an HDL-associated
enzyme which hydrolyzes the oxidized lipids in
LDL and organophosphate insecticides, pesti-
cides, and nerve gases. The PON1 gene is located
on chromosome 7q21.3-q22.1. The Q192R poly-
morphism influences the enzyme activity.
Carriers of RR192 genotype present with the
lowest ability to protect LDL from oxidation,
the lowest hydrolytic activity with diazoxon,
soman and sarin, and the highest with paraoxon
as compared with QQ genotype carriers (1).
Amyotrophic lateral sclerosis (ALS) is a fatal
disorder involving motor neurons. Oxidative
stress may play a role in the pathogenesis of
sporadic ALS (sALS). The levels of plasma lipid
peroxidation are increased in sALS patients com-
pared with those in controls (2). Moreover,
epidemiological studies suggest that chronic
exposure to environmental chemicals may be a
risk factor for sALS (3).
We hypothesize that slower hydrolysis of
environmental chemicals or increased oxidized
LDL levels in RR genotype carriers may corre-
late with increased risk of sALS. Therefore,
we studied the distribution of PON1 Q192R
polymorphism in sALS patients as compared to
that in controls.
We included 166 consecutive patients with defi-
nite or probable sALS (4) selected in the MND
Center, Jagiellonian University, who agreed to
participate in the study (87%). Four hundred
thirty-seven unrelated individuals, from the
population of Krakow, without any neurological
disease, excluded by structured questionnaire
and neurological examination, served as con-
trols. All cases and the controls were of
Caucasian origin and Polish descent. Controls
were matched to the cases with respect to the
age of the cases’ disease onset and sex. The
local Ethical Committee approved the study pro-
tocol. All individuals gave informed consent
before inclusion.
Leukocyte DNA was isolated using a commer-
cial kit (Boehringer Mannheim, Mannheim,
Germany). The Q192R genotyping for the PON1
genewasdetermined usingPCR-RFLPmethod (5).
Comparison of the genotype or allele frequency
between cases and controls was calculated by a
w2-test. Odds ratios (ORs) were calculated as a
measure of association of genotype with sALS
under assumptions of additive (assigning scores
of 0, 1, and 2 for QQ, QR, and RR, respectively),
dominant (score of 0 for QQ and 1 for QR and
RR combined), or recessive (score 0 for QQ and
QR combined and 1 for RR) mode of inheri-
tance. A p-value of <0.05 was considered statis-
tically significant.
The patients and the controls were of similar
age and sex distribution (Table 1). The Q192R
genotypes of PON1 gene in both groups were in
Hardy–Weinberg equilibrium.
No difference in genotype distribution was seen
between cases and controls (w22df ¼ 5.482,
p ¼ 0.065). R alleles were overrepresented in the
cases (w21df ¼ 4.703, p ¼ 0.03) (Table 1).
Logistic regression analysis carried out
under assumption of an additive (OR ¼ 1.36,
Table 1. Demographic data, genotype, and allele distribu-
tion in patients with sporadic amyotrophic lateral sclerosis
(sALS) and controls
Cases (n ¼ 166) Controls (n ¼ 437) p-value
Age (years) 56.2  13.1 57.9  17.7 0.25a
Sex (female) 79 (47.6%) 222 (50.8%) 0.44b
Genotypes
QQ 79 (47.6%) 240 (54.9%) 0.065b
QR 67 (40.4%) 167 (38.2%)
RR 20 (12.0%) 30 (6.9%)
Alleles
Q 225 (67.8%) 647 (74.0%) 0.03b
R 107 (32.2%) 227 (26.0%)
aStudent’s t-test.
bw2-test for a 2  k contingency table.
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95%CI ¼ 1.03–1.78, p ¼ 0.034) or recessive mode
of inheritance (OR ¼ 1.86, 95%CI ¼ 1.02–3.38,
p ¼ 0.04) showed a significant association between
phenotype and genotype with the R allele.
Our study results suggest that Q192R poly-
morphism of the PON1 gene influences the risk
of sALS in a Polish population. No correlation
was found between the Q192R polymorphism
and the age of sALS onset, the type of the disease
(bulbar vs limb onset), or its progression.
Chronic exposure to organophosphate com-
pounds in R allele carriers of PON1 gene may
result in their slower hydrolysis and, in conse-
quence, loss of vulnerable neuronal populations
such as motor neurons.
It cannot be excluded that slower hydrolysis of
nerve gases in R allele carriers may be responsible
for the increased risk of sALS in Gulf War
veterans (6). This hypothesis can be supported
by the significantly higher prevalence of the R
allele of the Q192R polymorphism in Gulf War
veterans with different neurological symptom
complexes (7).
It is also possible that the imbalance between
the antioxidant defense system and free radical
production, due to lower PON1 activity and
resultant increased levels of oxidized LDL,
increases the risk of sALS.
In our study, RR genotype carriers have 1.3
(additive model) and 1.8-fold (recessive model)
higher risk of sALS. This relation, however,
does not reach the suggested p < 0.01 for genetic
association studies. Our study results should be
interpreted with caution and it will be important
to replicate our finding in different populations.
The relation between exposure to different
environmental toxins and the levels of oxidized
LDL in ALS patients with respect to their PON1
Q192R genotypes should be investigated. Our
findings may provide a new direction for research
and generate new insights into ALS pathogenesis.
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